Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...5657585960616263646566...858859»
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion date, Trial primary completion date, Metastases:  Swedish Ibrance Registries Insights (SIRI) (clinicaltrials.gov) -  Jun 7, 2024   
    P=N/A,  N=1500, Recruiting, 
    Trial completion date: Dec 2022 --> Aug 2024 | Trial primary completion date: Dec 2022 --> Aug 2024
  • ||||||||||  dazodalibep (HZN-4920) / Amgen
    Enrollment open, Phase classification:  VIBRANT: VIB4920 for Active Lupus Nephritis (clinicaltrials.gov) -  Jun 6, 2024   
    P2,  N=74, Recruiting, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | Phase classification: P2a --> P2
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Nerlynx (neratinib) / Puma, Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Journal, PARP Biomarker:  Discovery of acetophenone/piperazin-2-one hybrids as selective anti-TNBC cancer agents by causing DNA damage. (Pubmed Central) -  Jun 6, 2024   
    In addition, 1j could selectively cause DNA damage, inducing the accumulation of ?H2AX and P53 in MDA-MB-468 cells. It also reduced the phosphorylation level of P38 and the expression of HSP70, which further prevented the repair of DNA damage and caused cells S/G2-arrest leading to MDA-MB-468 cells death.
  • ||||||||||  Tavalisse (fostamatinib) / Rigel
    Journal:  Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice. (Pubmed Central) -  Jun 6, 2024   
    One patient had deep venous thrombosis and one patient developed acute myocardial infarction. Fostamatinib was shown to be effective with good safety profile in patients with primary and secondary ITP across a wide age spectrum in this real-world study.
  • ||||||||||  palazestrant (OP-1250) / Olema Pharma
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  OP-1250-002: A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients (clinicaltrials.gov) -  Jun 6, 2024   
    P1,  N=60, Active, not recruiting, 
    Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Jan 2025 --> Dec 2025 Recruiting --> Active, not recruiting | N=30 --> 60 | Trial completion date: Dec 2023 --> Jul 2025 | Trial primary completion date: Jan 2023 --> Jan 2025
  • ||||||||||  Epogen (epoetin alfa) / Amgen
    Trial completion, Trial completion date, Trial primary completion date, Adverse events:  PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns (clinicaltrials.gov) -  Jun 4, 2024   
    P3,  N=313, Completed, 
    PCSK9i did not increase neurologic dysfunction, and did not elevate liver enzymes and CK, however it was associated with local injection site reaction. Active, not recruiting --> Completed | Trial completion date: Mar 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Nov 2023
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Biomarker, Clinical, Observational data, Retrospective data, Review, Clinical Trial,Phase I, Journal:  Pneumocystis jirovecii Pneumonia Secondary to Blinatumomab Therapy: A Case Report. (Pubmed Central) -  Jun 4, 2024   
    Despite prophylaxis, PCP infection cannot be ignored during blinatumomab therapy. Therefore, heightened attention is warranted when using blinatumomab therapy.
  • ||||||||||  ivabradine / Generic mfg.
    Journal:  GLP-1 increases heart rate by a direct action on the sinus node. (Pubmed Central) -  Jun 4, 2024   
    GLP-1 has direct chronotropic effects on the heart mediated by GLP-1 receptors in pacemaker cells of the sinus node, inducing changes in action potential morphology and the leading pacemaker site through a calcium signaling response characterized by PKA-dependent phosphorylation of Ca2+ cycling proteins involved in pace making. Targeting the pacemaker calcium clock may be a strategy to lower heart rate in GLP-1 RA recipients.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Darzalex (daratumumab) / J&J, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Review, Journal:  Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia. (Pubmed Central) -  Jun 4, 2024   
    These antibodies are currently being tested in patients with newly diagnosed ALL and may lead to major changes in the present paradigm of treatment of pediatric ALL. Unlike the past, lessons may be learned from innovations in adult ALL, in which more drastic changes are piloted that may need to be translated to pediatrics.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal:  Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia. (Pubmed Central) -  Jun 4, 2024   
    Challenges remain with using BiTE in a broader population although the appeal of now-confirmed reduced toxicity and deeper molecular remissions suggests that this approach will be an essential part of future treatment of childhood B-ALL. Herein, we review some of the pertinent literature covering clinical trials with blinatumomab and address future approaches and combination trials including BiTE.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial completion date, Trial primary completion date:  Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Jun 4, 2024   
    P1,  N=44, Active, not recruiting, 
    Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025 Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Mar 2025 --> Jun 2025
  • ||||||||||  Jakafi (ruxolitinib) / Incyte, Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Journal, Gene Signature:  Comprehensive analysis of gene signatures associated with aging in human aortic dissection. (Pubmed Central) -  Jun 3, 2024   
    By sequencing transcriptomic data, this study revealed aging-related hub genes and regulatory network involved in AD formation. Additionally, this study proposed a noteworthy hypothesis that downregulated ESR1 may exacerbate AD by promoting SMC aging, which requires further investigation.
  • ||||||||||  Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Cimzia (certolizumab pegol) / Astellas, UCB
    Review, Journal:  Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective. (Pubmed Central) -  Jun 3, 2024   
    (TNF-?) inhibitors, adalimumab, infliximab, and etanercept, are well studied in this patient population, and in some cases, HS was unresponsive to them...Also, golimumab showed promise in treating recalcitrant HS after the failure of other treatments, such as adalimumab and anti-interleukin-1. CPZ and golimumab can be efficacious treatment options for moderate-to-severe HS, especially in patients who are unresponsive to other TNF inhibitors, such as adalimumab.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Denosumab discontinuation: COVID-19 pandemic and beyond. (Pubmed Central) -  Jun 3, 2024   
    However, independent of the "emergency" that occurred during the COVID-19 pandemic, there are other situations in which denosumab is discontinued. In such situations, it is important to have a programmed strategy to optimize care while limiting the risk for unwanted outcomes.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    New P2 trial:  Blinatumomab Maintenance After Allo-HSCT (clinicaltrials.gov) -  Jun 2, 2024   
    P2,  N=59, Not yet recruiting, 
  • ||||||||||  Journal:  Triazole antifungal drug interactions-practical considerations for excellent prescribing. (Pubmed Central) -  Jun 2, 2024   
    We highlight interactions with drugs used in children and new agents introduced for the treatment of haematological malignancies or graft versus host disease (midostaurin, ibrutinib, ruxolitinib and venetoclax). We also summarize the multiple interactions between oral and inhaled corticosteroids and triazole antifungals, and the strategies needed to optimize the therapeutic benefits of triazole antifungal therapy while minimizing potential harm to patients.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Clinical, Journal:  Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials. (Pubmed Central) -  Jun 2, 2024   
    Inflammatory and ophthalmic composite outcome improvements were seen in 90% of patients with nearly 70% reporting improvement in diplopia and proptosis. Further, 82% of patients in this analysis did not report additional TED treatment (including surgery) over 99 weeks following the final teprotumumab dose.
  • ||||||||||  Kepivance (palifermin) / SOBI, Amgen
    Journal:  Recombinant Human Keratinocyte Growth Factor Ameliorates Cancer Treatment-Induced oral Mucositis on a Chip. (Pubmed Central) -  Jun 1, 2024   
    Palifermin, which is recombinant human keratinocyte growth factor (KGF), is currently the only mitigating treatment available to a subset of OM patients...Cisplatin, radiation, and combined treatments are followed by a recovery period in the OM-OC to determine possible cellular and molecular mechanisms of OM under effects of KGF...Cell damage, barrier dysfunction, and molecular expression during OM induction and resolution were assessed via widefield microscopy, viability and toxicity assays, and antibody arrays. Cell and molecular responses were identified during OM induction and resolution with and without KGF treatment at 1-10
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    Review, Journal:  Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? (Pubmed Central) -  Jun 1, 2024   
    Talimogene laherparepvec is an oncolytic herpes simplex virus type 1 (oHSV), approved for the treatment of recurrent melanoma, and the virus encodes the human cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF)...In this review, we highlight preliminary data with several cytokines and chemokines, including GM-CSF, interleukin 12, FMS-like tyrosine kinase 3 ligand, tumor necrosis factor ?, interleukin 2, interleukin 15, interleukin 18, chemokine (C-C motif) ligand 2, chemokine (C-C motif) ligand 5, chemokine (C-X-C motif) ligand 4, or their combinations, and show how these payloads can further enhance the antitumor immunity of oHSV. A better understanding of cytokine delivery by oHSV can help improve clinical benefit from oncolytic virus immunotherapy in patients with cancer.
  • ||||||||||  lunsekimig (SAR443765) / Sanofi
    TSLP AND IL-13 Dual Blockade By Lunsekimig Provides Broader Benefits On Type-2 Inflammation (PS-14; Poster board no. 20) -  May 31, 2024 - Abstract #ERS2024ERS_4807;    
    Indeed, lunsekimig was more potent in inhibiting TARC and eotaxin-3 production than targeting TSLP (tezepelumab) or IL-13 (lebrikizumab) alone in an allergen-stimulated triculture assay. Lunsekimig had significantly lowered plasma human IL
  • ||||||||||  pasotuxizumab (BAY2010112) / Amgen, Bayer
    Inhibition of the de-ubiquitinse USP30 in human fibroblasts from IPF patients suppresses the fibrotic response (PS-6; Poster board no. 13) -  May 31, 2024 - Abstract #ERS2024ERS_3796;    
    MTX112 at 10 and 30nM significantly (p<0.05) improved mitochondrial function by 50% in IPF fibroblasts. Targeting USP30 may therefore be a novel therapeutic strategy for the treatment of pulmonary fibrosis by improving pulmonary fibroblast mitochondrial function and slowing tissue fibrosis, potentially halting disease progression.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Tezepelumab reduces the expression of MUC5AC in patients with asthma (A1) -  May 31, 2024 - Abstract #ERS2024ERS_3516;    
    Anti-TSLP treatment reduces the expression of MUC5AC independent of T2-biomarker status, possibly through a downregulation of the EGFR pathway. This could mechanistically explain how tezepelumab reduces mucus plugging.